Clinical outcomes of immunohistochemistry of the p53 staining pattern in high-grade serous ovarian carcinoma

다국어 초록 (Multilingual Abstract)

ObjectiveTo investigate the prevalence of p53 mutations and associated factors between immunohistochemistry (IHC) and p53staining patterns among patients with high-grade serous ovarian carcinoma (HGSOC).
MethodsThis study is a retrospective review. A total of 62 patients with HGSOC underwent surgery at Srinagarind Hospitalbetween January 2016 and December 2020. Histological examination was performed based on a combination ofmorphology and IHC staining with p53. The p53 immunostaining pattern was interpreted as a missense mutation,nonsense mutation, or a wild-type pattern. Missense (p53 overexpression pattern) and nonsense (null expression p53pattern) mutations were considered p53 mutations. A wild-type pattern was defined as a p53 non-mutation.
Resultsp53 mutations were identified in 93.6% of the patients. Subgroup analysis of the p53 mutation group betweenthe p53 overexpression pattern and the p53 null expression pattern in terms of clinicopathological characteristicsand initial treatment was performed. Patients with the p53 overexpression pattern had significantly more omentalmetastases than those with the p53 null expression pattern (87.8% vs. 64.7%, P=0.042). There were no statisticallysignificant differences in median progression-free survival (PFS) (9 vs. 10 months, P=0.813) or median overall survival(OS) (12 vs. 17 months, P=0.526) between the two groups.
ConclusionThe prevalence of p53 mutations in HGSOC patients in this study was 93.6%. Omental metastasis is a significantpathological factor in predicting overexpression p53 pattern in HGSC. However, IHC analysis of the p53 stainingpattern did not affect OS or PFS among patients with HGSOC.

참고문헌 (Reference)

1 Kurman RJ, "The dualistic model of ovarian carcinogenesis : revisited, revised, and expanded" 186 : 733-747, 2016

2 Kuhn E, "TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions" 226 : 421-426, 2012

3 Na K, "TP53 mutation status of tuboovarian and peritoneal high-grade serous carcinoma with a wild-type p53 immunostaining pattern" 37 : 6697-6703, 2017

4 Chompret A, "Sensitivity and predictive value of criteria for p53 germline mutation screening" 38 : 43-47, 2001

5 Emre Günakan ; Yusuf Aytaç Tohma ; Latife Atasoy Karakaş ; Hüseyin Akıllı ; Asuman Nihan Haberal ; Ali Ayhan, "Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer" 대한산부인과학회 63 (63): 464-469, 2020

6 Roshni D. Kalachand ; Ciaran O’Riain ; Sinead Toomey ; Aoife Carr ; Kirsten M. Timms ; Sharon O’Toole ; Stephen Madden ; Mark Bates ; John J. O’Leary ; Noreen Gleeson ; Dearbhaile O’Donnell ; Liam Grogan ; Oscar Breathnach ; Angela Farrelly ; Britta Stordal ; Bryan T. Hennessy, "Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer" 대한산부인과학회 63 (63): 643-654, 2020

7 Köbel M, "Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry" 64 : 1004-1013, 2014

8 Torre LA, "Ovarian cancer statistics, 2018" 68 : 284-296, 2018

9 Menon U, "Ovarian cancer prevention and screening" 131 : 909-927, 2018

10 Lengyel E, "Ovarian cancer development and metastasis" 177 : 1053-1064, 2010

11 Matulonis UA, "Ovarian cancer" 2 : 16061-, 2016

12 Kurman RJ, "Origin and molecular pathogenesis of ovarian high-grade serous carcinoma" 24 : 16-21, 2013

13 Banerjee S, "New strategies in the treatment of ovarian cancer : current clinical perspectives and future potential" 19 : 961-968, 2013

14 Vang R, "Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma : a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study" 35 : 48-55, 2016

15 Pereira A, "International federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum : estimation of survival in patients with node-positive epithelial ovarian cancer" 25 : 49-54, 2015

16 Yemelyanova A, "Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma : an immunohistochemical and nucleotide sequencing analysis" 24 : 1248-1253, 2011

17 Peres LC, "Histotype classification of ovarian carcinoma : a comparison of approaches" 151 : 53-60, 2018

18 Lisio MA, "Highgrade serous ovarian cancer : basic sciences, clinical and therapeutic standpoints" 20 : 952-, 2019

19 Vang R, "Fallopian tube precursors of ovarian low-and high-grade serous neoplasms" 62 : 44-58, 2013

20 Lheureux S, "Epithelial ovarian cancer : evolution of management in the era of precision medicine" 69 : 280-304, 2019

21 Horowitz NS, "Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182" 33 : 937-943, 2015

22 Hu J, "Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?" 81 : 515-520, 2013

23 Ring KL, "Current and future role of genetic screening in gynecologic malignancies" 217 : 512-521, 2017

24 Narod S, "Can advanced-stage ovarian cancer be cured?" 13 : 255-261, 2016

25 Gilbert L, "Assessment of symptomatic women for early diagnosis of ovarian cancer : results from the prospective DOvE pilot project" 13 : 285-291, 2012

26 Cole AJ, "Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing" 6 : 26191-, 2016

27 Nieman KM, "Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth" 17 : 1498-1503, 2011

28 Casey L, "A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy" 71 : 736-742, 2017